Abstract

The present disclosure relates to methods and kits for diagnosing,monitoring, and evaluating appropriate therapies against chronic graft-versus-host disease (cGvHD) in patients who have received an allogeneic cell transplantation such as allogeneic hematopoietic stem cell transplantation (allo-HSCT). These methods can be used for determining the patients who may respond to a treatment of cGvHD that is based on Arsenic Trioxide (ATO), such method consisting in measuring the expression levels of one or more cytokines (such as CCL4, alone or combined to one or more cytokines selected from GM-CSF, IL-1α/IL-1alpha, IL-17A, IL-21, and CXCL1) in a biological sample from the patients affected by cGvHD after having received the allogeneic cell transplantation.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 33/242 - GoldCompounds thereof
• A61K 33/26 - IronCompounds thereof
• A61K 33/30 - ZincCompounds thereof
• A61K 33/32 - ManganeseCompounds thereof
• A61K 33/34 - CopperCompounds thereof
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.

IPC Classes  ?

• A61K 31/285 - Arsenic compounds
• A61K 31/28 - Compounds containing heavy metals
• A61K 31/30 - Copper compounds
• A61K 31/315 - Zinc compounds
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 33/242 - GoldCompounds thereof
• A61K 33/26 - IronCompounds thereof
• A61K 33/30 - ZincCompounds thereof
• A61K 33/32 - ManganeseCompounds thereof
• A61K 33/34 - CopperCompounds thereof
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.

IPC Classes  ?

• A61K 31/285 - Arsenic compounds
• A61K 33/242 - GoldCompounds thereof
• A61K 31/30 - Copper compounds
• A61K 31/315 - Zinc compounds
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61K 33/242 - GoldCompounds thereof
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 33/26 - IronCompounds thereof
• A61K 33/30 - ZincCompounds thereof
• A61K 33/32 - ManganeseCompounds thereof
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 33/242 - GoldCompounds thereof
• A61K 33/26 - IronCompounds thereof
• A61K 33/30 - ZincCompounds thereof
• A61K 33/32 - ManganeseCompounds thereof
• A61K 33/34 - CopperCompounds thereof
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention relates to a method for preventing or treating multiple sclerosis, particularly relapsing-remitting multiple sclerosis using arsenic trioxide.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to a method for preventing or treating multiple sclerosis, particularly relapsing-remitting multiple sclerosis using arsenic trioxide.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/00 - Drugs for immunological or allergic disorders